Summary Response Assessment in Neuro-Oncology (RANO) response criteria have been
established and were updated in 2023 for MRI-based response evaluation of diffuse …

These joint practice guidelines, or procedure standards, were developed collaboratively by
the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and …

The Response Assessment in Neuro-Oncology Working Group has analysed the role of
clinically established PET methods in the diagnostic assessment of brain tumours. The …

Imaging techniques are important for accurate diagnosis and follow-up of patients with
gliomas. T1-weighted MRI, with or without gadolinium, is the gold standard method …

Positron emission tomography (PET) is a nuclear medicine imaging method with increasing
relevance for the diagnosis, prognostication, and monitoring of glioblastomas. PET provides …

This guideline provides recommendations for the use of PET imaging in gliomas. The review
examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) …

The response assessment in neuro-oncology (RANO) criteria have been the gold standard
for monitoring treatment response in glioblastoma (GBM) and differentiating tumor …

Although rare, glioblastomas account for the majority of primary brain lesions, with a
dreadful prognosis. Magnetic resonance imaging (MRI) is currently the imaging method …

Purpose Gliomas constitute the most frequent primary brain tumors. Glioblastoma, the most
common and malignant glioma in adults, has dismal prognosis with any current therapy. On …

Evaluation of metabolic tumor volume (MTV) changes using amino acid PET has become an
important tool for response assessment in brain tumor patients. MTV is usually determined …